Marcel Wuethrich

Marcel Wuethrich has over 30 years of experience in the healthcare industry. Marcel began their career in 1991 at RONDO Burgdorf AG in Sales & Marketing Support Functions. In 1995, they moved to Disetronic Medical Systems as a Sales & Export employee. In 1997, they became a Junior Product Manager Cardio at Disetronic Medical Systems Burgdorf. In 1999, they were promoted to Head of Marketing at Disetronic Medical Systems. In 2004, they joined Roche where they held several roles such as Country Manager Belgium & Finland / Roche Diagnostics Brussels, Country Manager Finland / Roche Diagnostics Helsinki, Head of Marketing, Customer Care & Technical Sales/Training Roche Diagnostics, and Head Business Management, Customer Services & Strategic Projects Europe, Middle East, Africa, LATAM. In 2022, they joined evoleen as the Head of Business Unit Pharma & Diagnostics. In this role, they are responsible for leading the Global Business Unit Pharma & Diagnostics with full P&L responsibility, leading multidisciplinary venture co-creation teams and projects with leading pharma, diagnostics & medtech companies, leading business teams and projects in all relevant phases, representing Evoleen as a board member in its ventures and providing strategic guidance, leading go to market strategy development, building a strong partner network, and team building and development.

Marcel Wuethrich is currently enrolled in an Executive Master of Business Administration (EMBA) program at IMD and the University of Lausanne Switzerland, studying Business Administration, Management and Operations. Marcel also completed an Advanced Management Concepts module (AMC), Executive Master Studies EMBA at IMD in 2021, and a FBL Foundations in Business Leadership program at IMD in 2020. In 2007-2010, Marcel attended the Höhere Fachschule für Business Administration - Higher institute of Business Administration. In 1997-1998, Marcel completed a Marketing Planning program at the Swiss Marketing Institute. Additionally, Marcel obtained an ESG Impact Investing certification from IMD in March 2021.